ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem that we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two
-
PATIENT SPOTLIGHT: Ruby Blow, Atlanta, GA, USA
Please enjoy our interview with the wonderful and courageous Ruby Blow! 1) Share with us a little bit about yourself, including your personal life, your professional background, and your journey
-
Butternut Squash, Spinach, and Spicy Sausage Soup with Orzo Recipe
This comforting soup makes a delicious and savory soup that’s perfect for those cold busy nights in the Fall and Winter when butternut squash is also in season. *feel free to substitute sweet pork sausage in this recipe if spicy isn’t your thing! One pot – 30 minutes start to finish!
-
A New Clinical Trial in Italy: Does Supervised Exercise Improve Outcomes in Oncogene Addicted Lung Cancer?
For those diagnosed with advanced lung cancer, there is often the question of how lifestyle changes can improve the prognosis. A unique study in Italy called EXcellenT will measure how
-
FDA approves crizotinib for ALK-positive inflammatory myogibroblastic tumor
On July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory
-
The Latest & Greatest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from
-
ALKOVE Clinical Trial: a 4th Generation TKI from Nuvalent
The Phase 1/2 trial of Nuvalent, Inc.’s NVL-655, the fourth generation ALK TKI, has begun at Sarah Cannon Research Institute in Nashville, soon to be followed by additional locations. Below
-
ALK Positive Inc. at ASCO (June 3-7, 2022)
“Going to ASCO was a great opportunity to network and represent the organization, help move ALK to the top, and let people know who we are. I feel it was
-
PATIENT SPOTLIGHT: Emily Venanzi, Newton, Massachussetts
Emily Venanzi is an active member of our Medical Commitee (with particular involvement in the Research Review Panel selecting which research projects to fund) as well as our Research Accelaration
-
Chemotherapy 101
One of the challenges in our community has been the treatment of earlier stages of ALK-positive lung cancer, including stages IA through 3A. Historically, we’ve faced a lack of definitive guidelines for addressing the illness that represents 30-40% of the total ALK lung cancer population. Patients in these stages are traditionally treated with surgical tumor…
-
The latest from ALK Positive Inc.
May 14, 2022 ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of
-
PATIENT SPOTLIGHT: Nancee Pronsati, Golden, Colorado, USA
Nancee has been an ALK patient for the last 6 years, and she is an incredible member of the ALK community who is devoting her time and resources to multiple